Subgroup Spin and Authorship in a Failed Phase 3 Trial
A medical writer is drafting a manuscript for a Phase 3 trial of a chronic kidney disease drug. The trial randomized 612 patients; the primary endpoint (eGFR slope over 24 months) missed significance (p=0.11). A prespecified subgroup of 148 patients with baseline proteinuria above 1.5 g/g showed a 32% reduction in a secondary composite endpoint (p=0.03), but the trial's alpha was not allocated to that subgroup. The sponsor's publication committee wants the title to read 'Significant renal benefit in high-risk patients' and wants to add a commercial statistician as an author because she 'ran the subgroup analysis,' although she did not draft, revise, or approve the manuscript and cannot meet ICMJE criteria. The committee also wants to delay submission until after a regulatory advisory committee meeting in four months and to omit the primary endpoint from the abstract. The lead investigator is uncomfortable but has not objected in writing.
1. How should the writer handle the title, abstract, and subgroup result?
Read the worked answer
The primary endpoint is the trial's prespecified measure and must be reported honestly, including the p=0.11 result and the confidence interval. A subgroup p=0.03 without a prespecified alpha allocation is exploratory; it does not support a claim of 'significant renal benefit' in the title. The title should reflect the randomized trial and the primary result, for example, 'No significant effect on eGFR slope...' with the subgroup identified in the abstract as hypothesis-generating. Omitting the primary endpoint from the abstract would be selective reporting and could mislead readers and regulators. Abstract: include primary endpoint, key secondary outcomes, safety, and limitations; report the subgroup with its unadjusted p-value and interaction test if available. Reasoning: readers and guideline panels need the whole result; spin in titles propagates into news and prescribing. The writer should raise the issue with the lead investigator and publication committee in writing.
2. How should authorship be decided for the commercial statistician?
Read the worked answer
Apply ICMJE authorship criteria: substantial contributions to conception/design or acquisition/analysis/interpretation; drafting or critical revision; final approval; and agreement to be accountable. A statistician who ran the subgroup analysis may meet the analysis criterion, but not if she did not review and approve the manuscript or cannot be accountable. The commercial statistician's employment does not disqualify her, but commercial affiliation is not a reason to add her either. If she does not meet all four criteria, list her in acknowledgments with permission. The sponsor cannot gift authorship to reward commercial work. Process: collect disclosure forms, confirm each author's contribution, and document the decision. If the committee insists, the writer should escalate to the publication steering committee and compliance. Guest authorship undermines credibility and journal policies.
3. What should the writer do about the proposed delay and omission of the primary endpoint?
Read the worked answer
Delaying submission until after an advisory committee may be legitimate for scientific or regulatory reasons, but it must not be used to suppress negative results. The trial is registered; results should be posted in the registry within the required timeframe (often 12 months of completion) regardless of manuscript status. Omitting the primary endpoint is not acceptable. Reasoning: negative trials matter for guidelines and future research; selective delay can distort the evidence base. The writer should propose a timeline: submit the full manuscript with the primary result now, or if a justified delay exists, document the reason and ensure registry disclosure. She should ask the lead investigator to put concerns in writing. If the committee still wants spin or omission, escalate to the institution and journal ethics office as appropriate.